Regulus Therapeutics has signed its second deal in the space of a few days by partnering with Biogen Idec to identify microRNAs as biomarkers for multiple sclerosis. These biomarkers could have utility in selecting optimal patient segments in clinical trials, developing companion diagnostics and monitoring disease progression and relapse. Regulus’ other partners include AstraZeneca, Sanofi and GlaxoSmithKline but its previous deals have focused on the discovery and development of miRNA therapeutics.